177 related articles for article (PubMed ID: 26837440)
21. Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine.
Banchereau J; Palucka AK; Dhodapkar M; Burkeholder S; Taquet N; Rolland A; Taquet S; Coquery S; Wittkowski KM; Bhardwaj N; Pineiro L; Steinman R; Fay J
Cancer Res; 2001 Sep; 61(17):6451-8. PubMed ID: 11522640
[TBL] [Abstract][Full Text] [Related]
22. Route of administration modulates the induction of dendritic cell vaccine-induced antigen-specific T cells in advanced melanoma patients.
Lesterhuis WJ; de Vries IJ; Schreibelt G; Lambeck AJ; Aarntzen EH; Jacobs JF; Scharenborg NM; van de Rakt MW; de Boer AJ; Croockewit S; van Rossum MM; Mus R; Oyen WJ; Boerman OC; Lucas S; Adema GJ; Punt CJ; Figdor CG
Clin Cancer Res; 2011 Sep; 17(17):5725-35. PubMed ID: 21771874
[TBL] [Abstract][Full Text] [Related]
23. A multi-trimeric fusion of CD40L and gp100 tumor antigen activates dendritic cells and enhances survival in a B16-F10 melanoma DNA vaccine model.
Gupta S; Termini JM; Rivas Y; Otero M; Raffa FN; Bhat V; Farooq A; Stone GW
Vaccine; 2015 Sep; 33(38):4798-806. PubMed ID: 26241951
[TBL] [Abstract][Full Text] [Related]
24. Are dysfunctional monocyte-derived dendritic cells in cancer an explanation for cancer vaccine failures?
Barbuto JA
Immunotherapy; 2013 Feb; 5(2):105-7. PubMed ID: 23413899
[No Abstract] [Full Text] [Related]
25. Immunogenetic therapy of human melanoma utilizing autologous tumor cells transduced to secrete granulocyte-macrophage colony-stimulating factor.
Chang AE; Li Q; Bishop DK; Normolle DP; Redman BD; Nickoloff BJ
Hum Gene Ther; 2000 Apr; 11(6):839-50. PubMed ID: 10779161
[TBL] [Abstract][Full Text] [Related]
26. Surveillance of the eye and vision in a clinical trial of MART1-transformed dendritic cells for metastatic melanoma.
Gordon LK; Ribas A; Nusinowitz S; Butterfield LH; Glaspy JA; Economou JS; Straatsma BR
Control Clin Trials; 2004 Aug; 25(4):400-7. PubMed ID: 15296814
[TBL] [Abstract][Full Text] [Related]
27. Vaccination with melanoma lysate-pulsed dendritic cells, of patients with advanced colorectal carcinoma: report from a phase I study.
Burgdorf SK; Fischer A; Claesson MH; Kirkin AF; Dzhandzhugazyan KN; Rosenberg J
J Exp Clin Cancer Res; 2006 Jun; 25(2):201-6. PubMed ID: 16918131
[TBL] [Abstract][Full Text] [Related]
28. Vaccination with irradiated, autologous melanoma cells engineered to secrete granulocyte-macrophage colony-stimulating factor by adenoviral-mediated gene transfer augments antitumor immunity in patients with metastatic melanoma.
Soiffer R; Hodi FS; Haluska F; Jung K; Gillessen S; Singer S; Tanabe K; Duda R; Mentzer S; Jaklitsch M; Bueno R; Clift S; Hardy S; Neuberg D; Mulligan R; Webb I; Mihm M; Dranoff G
J Clin Oncol; 2003 Sep; 21(17):3343-50. PubMed ID: 12947071
[TBL] [Abstract][Full Text] [Related]
29. Immune responses in the draining lymph nodes against cancer: implications for immunotherapy.
Shu S; Cochran AJ; Huang RR; Morton DL; Maecker HT
Cancer Metastasis Rev; 2006 Jun; 25(2):233-42. PubMed ID: 16770535
[TBL] [Abstract][Full Text] [Related]
30. Immunotherapy of cancer with dendritic cells loaded with tumor antigens and activated through mRNA electroporation.
Van Nuffel AM; Corthals J; Neyns B; Heirman C; Thielemans K; Bonehill A
Methods Mol Biol; 2010; 629():405-52. PubMed ID: 20387165
[TBL] [Abstract][Full Text] [Related]
31. Phase I trial of Lipovaxin-MM, a novel dendritic cell-targeted liposomal vaccine for malignant melanoma.
Gargett T; Abbas MN; Rolan P; Price JD; Gosling KM; Ferrante A; Ruszkiewicz A; Atmosukarto IIC; Altin J; Parish CR; Brown MP
Cancer Immunol Immunother; 2018 Sep; 67(9):1461-1472. PubMed ID: 30014244
[TBL] [Abstract][Full Text] [Related]
32. Dendritic cell-derived exosomes in cancer immunotherapy: exploiting nature's antigen delivery pathway.
Delcayre A; Shu H; Le Pecq JB
Expert Rev Anticancer Ther; 2005 Jun; 5(3):537-47. PubMed ID: 16001959
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of melanoma vaccines with molecularly defined antigens by ex vivo monitoring of tumor-specific T cells.
Speiser DE; Pittet MJ; Rimoldi D; Guillaume P; Luescher IF; Liénard D; Lejeune F; Cerottini JC; Romero P
Semin Cancer Biol; 2003 Dec; 13(6):461-72. PubMed ID: 15001165
[TBL] [Abstract][Full Text] [Related]
34. Vaccine therapy for patients with melanoma.
Haigh PI; Difronzo LA; Gammon G; Morton DL
Oncology (Williston Park); 1999 Nov; 13(11):1561-74; discussion 1574 passim. PubMed ID: 10581603
[TBL] [Abstract][Full Text] [Related]
35. Vaccines and melanoma.
Ott PA; Fritsch EF; Wu CJ; Dranoff G
Hematol Oncol Clin North Am; 2014 Jun; 28(3):559-69. PubMed ID: 24880947
[TBL] [Abstract][Full Text] [Related]
36. [Vaccinal cell therapy in melanoma].
Quillien V; Lesimple T; Toujas L
Bull Cancer; 2003; 90(8-9):722-33. PubMed ID: 14609762
[TBL] [Abstract][Full Text] [Related]
37. Towards a standardized protocol for the generation of monocyte-derived dendritic cell vaccines.
Erdmann M; Schuler-Thurner B
Methods Mol Biol; 2010; 595():149-63. PubMed ID: 19941110
[TBL] [Abstract][Full Text] [Related]
38. [Vaccine strategies against melanoma].
Ghiringhelli F; Zitvogel L
Med Sci (Paris); 2006 Feb; 22(2):183-7. PubMed ID: 16457760
[TBL] [Abstract][Full Text] [Related]
39. Melanoma vaccines.
Yang JC
Cancer J; 2011; 17(5):277-82. PubMed ID: 21952276
[TBL] [Abstract][Full Text] [Related]
40. Sipuleucel-T (Provenge) autologous vaccine approved for treatment of men with asymptomatic or minimally symptomatic castrate-resistant metastatic prostate cancer.
Gardner TA; Elzey BD; Hahn NM
Hum Vaccin Immunother; 2012 Apr; 8(4):534-9. PubMed ID: 22832254
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
